Supernus End Period Cash Flow vs Capital Expenditures Analysis

SUPN Stock

USD 36.74 0.06 0.16%

Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals End Period Cash Flow and its Capital Expenditures accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

End Period Cash Flow vs Capital Expenditures

End Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals End Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Supernus Pharmaceuticals' End Period Cash Flow and Capital Expenditures is 0.54. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' End Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Supernus Pharmaceuticals are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of End Period Cash Flow i.e., Supernus Pharmaceuticals' End Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

End Period Cash Flow

Capital Expenditures

Capital Expenditures are funds used by Supernus Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Supernus Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Tax Provision is likely to grow to about 17.1 M, while Sales General And Administrative To Revenue is likely to drop 0.37.

	2021	2022	2023	2024 (projected)
Interest Expense	23.4M	7.1M	2.4M	2.3M
Depreciation And Amortization	32.6M	85.6M	84.9M	89.1M

Interest Expense Depreciation And Amortization

Supernus Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock
Common Stock Shares Outstanding		0.68	0.5	0.5	0.61	0.63	0.42	0.42	0.47	-0.27	0.46	0.63	-0.14	0.64	0.7	0.93	0.6	0.41	0.58	0.47	0.91	0.61	0.53	0.69	0.45	0.94
Total Assets	0.68		0.85	0.8	0.85	0.89	0.64	0.8	0.85	-0.07	0.69	0.96	-0.47	0.95	0.92	0.65	0.85	0.75	0.84	0.8	0.88	0.97	0.86	0.99	0.8	0.65
Short Long Term Debt Total	0.5	0.85		0.5	0.7	0.59	0.34	0.93	0.56	0.16	0.77	0.75	-0.53	0.91	0.66	0.42	0.74	0.86	0.53	0.69	0.66	0.94	0.67	0.87	0.49	0.45
Other Current Liab	0.5	0.8	0.5		0.73	0.91	0.65	0.5	0.91	-0.3	0.44	0.88	-0.36	0.71	0.91	0.49	0.68	0.44	0.95	0.71	0.69	0.74	0.72	0.78	0.94	0.47
Total Current Liabilities	0.61	0.85	0.7	0.73		0.77	0.41	0.79	0.78	0.03	0.31	0.8	-0.42	0.82	0.82	0.54	0.94	0.36	0.83	0.53	0.7	0.81	0.65	0.87	0.78	0.54
Total Stockholder Equity	0.63	0.89	0.59	0.91	0.77		0.84	0.57	0.97	-0.26	0.53	0.97	-0.27	0.82	0.98	0.63	0.77	0.51	0.94	0.67	0.81	0.81	0.9	0.87	0.89	0.61
Property Plant And Equipment Net	0.42	0.64	0.34	0.65	0.41	0.84		0.27	0.82	-0.28	0.48	0.76	0.08	0.58	0.75	0.46	0.47	0.41	0.68	0.48	0.61	0.54	0.89	0.61	0.64	0.43
Net Debt	0.42	0.8	0.93	0.5	0.79	0.57	0.27		0.58	0.17	0.51	0.71	-0.61	0.85	0.62	0.3	0.83	0.68	0.58	0.56	0.55	0.88	0.61	0.82	0.53	0.32
Retained Earnings	0.47	0.85	0.56	0.91	0.78	0.97	0.82	0.58		-0.24	0.44	0.94	-0.28	0.78	0.94	0.46	0.75	0.46	0.94	0.64	0.69	0.78	0.88	0.83	0.92	0.43
Accounts Payable	-0.27	-0.07	0.16	-0.3	0.03	-0.26	-0.28	0.17	-0.24		-0.02	-0.15	-0.28	-0.03	-0.27	-0.12	0.03	0.03	-0.21	-0.01	-0.15	0.01	-0.08	-0.08	-0.15	-0.09
Cash	0.46	0.69	0.77	0.44	0.31	0.53	0.48	0.51	0.44	-0.02		0.65	-0.27	0.75	0.58	0.47	0.36	0.92	0.35	0.74	0.64	0.76	0.64	0.7	0.35	0.51
Non Current Assets Total	0.63	0.96	0.75	0.88	0.8	0.97	0.76	0.71	0.94	-0.15	0.65		-0.43	0.89	0.97	0.61	0.79	0.68	0.92	0.8	0.83	0.92	0.92	0.93	0.89	0.6
Non Currrent Assets Other	-0.14	-0.47	-0.53	-0.36	-0.42	-0.27	0.08	-0.61	-0.28	-0.28	-0.27	-0.43		-0.38	-0.31	-0.12	-0.34	-0.51	-0.4	-0.65	-0.29	-0.55	-0.29	-0.42	-0.45	-0.14
Cash And Short Term Investments	0.64	0.95	0.91	0.71	0.82	0.82	0.58	0.85	0.78	-0.03	0.75	0.89	-0.38		0.87	0.61	0.88	0.76	0.72	0.68	0.83	0.96	0.8	0.98	0.66	0.62
Net Receivables	0.7	0.92	0.66	0.91	0.82	0.98	0.75	0.62	0.94	-0.27	0.58	0.97	-0.31	0.87		0.66	0.79	0.56	0.93	0.71	0.85	0.86	0.85	0.92	0.88	0.66
Common Stock Total Equity	0.93	0.65	0.42	0.49	0.54	0.63	0.46	0.3	0.46	-0.12	0.47	0.61	-0.12	0.61	0.66		0.57	0.38	0.54	0.47	0.93	0.55	0.53	0.66	0.43	0.99
Short Term Investments	0.6	0.85	0.74	0.68	0.94	0.77	0.47	0.83	0.75	0.03	0.36	0.79	-0.34	0.88	0.79	0.57		0.41	0.76	0.43	0.73	0.81	0.66	0.89	0.67	0.56
Non Current Liabilities Total	0.41	0.75	0.86	0.44	0.36	0.51	0.41	0.68	0.46	0.03	0.92	0.68	-0.51	0.76	0.56	0.38	0.41		0.4	0.81	0.62	0.83	0.66	0.73	0.4	0.41
Inventory	0.58	0.84	0.53	0.95	0.83	0.94	0.68	0.58	0.94	-0.21	0.35	0.92	-0.4	0.72	0.93	0.54	0.76	0.4		0.69	0.73	0.77	0.8	0.81	0.97	0.53
Other Current Assets	0.47	0.8	0.69	0.71	0.53	0.67	0.48	0.56	0.64	-0.01	0.74	0.8	-0.65	0.68	0.71	0.47	0.43	0.81	0.69		0.68	0.83	0.73	0.74	0.75	0.48
Other Stockholder Equity	0.91	0.88	0.66	0.69	0.7	0.81	0.61	0.55	0.69	-0.15	0.64	0.83	-0.29	0.83	0.85	0.93	0.73	0.62	0.73	0.68		0.8	0.75	0.87	0.64	0.92
Total Liab	0.61	0.97	0.94	0.74	0.81	0.81	0.54	0.88	0.78	0.01	0.76	0.92	-0.55	0.96	0.86	0.55	0.81	0.83	0.77	0.83	0.8		0.82	0.97	0.74	0.57
Property Plant And Equipment Gross	0.53	0.86	0.67	0.72	0.65	0.9	0.89	0.61	0.88	-0.08	0.64	0.92	-0.29	0.8	0.85	0.53	0.66	0.66	0.8	0.73	0.75	0.82		0.82	0.77	0.53
Total Current Assets	0.69	0.99	0.87	0.78	0.87	0.87	0.61	0.82	0.83	-0.08	0.7	0.93	-0.42	0.98	0.92	0.66	0.89	0.73	0.81	0.74	0.87	0.97	0.82		0.75	0.66
Intangible Assets	0.45	0.8	0.49	0.94	0.78	0.89	0.64	0.53	0.92	-0.15	0.35	0.89	-0.45	0.66	0.88	0.43	0.67	0.4	0.97	0.75	0.64	0.74	0.77	0.75		0.42
Common Stock	0.94	0.65	0.45	0.47	0.54	0.61	0.43	0.32	0.43	-0.09	0.51	0.6	-0.14	0.62	0.66	0.99	0.56	0.41	0.53	0.48	0.92	0.57	0.53	0.66	0.42

Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	53.8M	53.7M	54.4M	61.7M	55.5M	42.6M
Total Assets	1.2B	1.5B	1.7B	1.7B	1.3B	676.1M
Short Long Term Debt Total	375.6M	390.3M	420.6M	438.0M	41.5M	39.5M
Other Current Liab	3.2M	226.1M	292.3M	268.7M	279.9M	293.9M
Total Current Liabilities	160.6M	245.1M	315.4M	688.0M	290.2M	154.7M
Total Stockholder Equity	595.4M	744.9M	815.9M	886.2M	921.5M	967.6M
Property Plant And Equipment Net	38.3M	37.8M	17.0M	15.2M	42.5M	44.7M
Net Debt	194.2M	101.7M	217.1M	344.8M	(33.5M)	(31.9M)
Retained Earnings	199.5M	326.5M	379.9M	481.2M	482.6M	506.7M
Accounts Payable	10.1M	6.1M	9.3M	10.5M	2.0M	1.9M
Cash	181.4M	288.6M	203.4M	93.1M	75.1M	116.1M
Non Current Assets Total	687.6M	873.7M	1.1B	968.4M	784.6M	823.8M
Non Currrent Assets Other	615K	8.0M	(36.1M)	(10.0M)	8.5M	8.9M
Cash And Short Term Investments	347.1M	422.5M	339.7M	461.3M	254.9M	201.2M
Net Receivables	87.3M	140.9M	148.9M	165.5M	144.2M	151.4M
Common Stock Total Equity	51K	52K	53K	54K	62.1K	40.8K
Short Term Investments	165.7M	133.9M	136.2M	368.2M	179.8M	98.1M
Liabilities And Stockholders Equity	1.2B	1.5B	1.7B	1.7B	1.3B	676.1M
Non Current Liabilities Total	404.3M	514.1M	557.9M	128.3M	66.0M	62.7M
Inventory	26.6M	48.3M	86.0M	91.5M	77.4M	81.3M
Other Current Assets	11.6M	37.4M	54.0M	15.8M	16.7M	11.7M
Other Stockholder Equity	388.4M	409.3M	434.3M	408.1M	439.5M	279.8M
Total Liab	564.9M	759.2M	873.3M	816.3M	356.2M	324.8M
Property Plant And Equipment Gross	38.3M	37.8M	33.4M	28.2M	28.9M	30.4M
Total Current Assets	472.6M	630.4M	601.6M	734.2M	493.1M	305.3M
Accumulated Other Comprehensive Income	7.4M	9.0M	1.5M	(3.2M)	(593K)	(563.4K)
Intangible Assets	24.8M	442.3M	784.7M	702.5M	599.9M	629.9M
Common Stock	51K	52K	53K	54K	55K	42.0K
Other Liab	28.7M	123.8M	137.4M	92.3M	106.2M	111.5M
Current Deferred Revenue	144.4M	122.4M	126.2M	49.8M	1.0	0.95
Other Assets	32.7M	259.7M	13.9M	10.9M	12.5M	11.9M
Long Term Debt	329.5M	345.2M	361.8M	379.3M	436.1M	457.9M
Short Term Debt	2.8M	12.8M	13.7M	408.8M	8.3M	7.9M
Property Plant Equipment	17.1M	37.8M	52.3M	44.1M	50.7M	53.2M
Net Tangible Assets	570.6M	302.6M	(86.4M)	66.7M	76.7M	72.9M
Good Will	24.8M	77.9M	117.5M	117.0M	134.6M	141.3M
Retained Earnings Total Equity	199.5M	326.5M	379.9M	481.2M	553.4M	581.1M
Capital Surpluse	388.4M	409.3M	434.3M	408.1M	469.3M	352.1M

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Supernus Stock

0.77	ESPR	Esperion Therapeutics	Pair Corr
0.87	BMY	Bristol Myers Squibb	Pair Corr

Moving against Supernus Stock

0.89	TTOO	T2 Biosystms	Pair Corr
0.86	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.85	AKAN	Akanda Corp	Pair Corr
0.82	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.78	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.

The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

1.07

Revenue Per Share

11.877

Quarterly Revenue Growth

0.142

Return On Assets

0.0289

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus End Period Cash Flow vs Capital Expenditures Analysis

End Period Cash Flow vs Capital Expenditures

End Period Cash Flow vs Capital Expenditures Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Capital Expenditures

Supernus Pharmaceuticals fundamental ratios Correlations

Supernus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Supernus Pharmaceuticals fundamental ratios Accounts

Pair Trading with Supernus Pharmaceuticals

Moving together with Supernus Stock

Moving against Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Common Stock Total Equity
Net Receivables	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Liab	+ 0.97	Total Assets
Retained Earnings	+ 0.97	Total Stockholder Equity

Other Current Assets	- 0.65	Non Currrent Assets Other
Non Currrent Assets Other	- 0.61	Net Debt
Total Liab	- 0.55	Non Currrent Assets Other
Non Currrent Assets Other	- 0.53	Short Long Term Debt Total
Non Current Liabilities Total	- 0.51	Non Currrent Assets Other
Non Currrent Assets Other	- 0.47	Total Assets